Northwest Biotherapeutics develops DCVax® personalized immune therapies for solid tumor cancers. News about NWBO centers on its dendritic cell-based cancer vaccine platform, including DCVax-L for glioblastoma and DCVax-Direct for inoperable solid tumors, along with scientific presentations on next-generation dendritic cell treatments.
Company updates also cover manufacturing and treatment-logistics capacity for cell therapies, including the Sawston, UK facility, leukapheresis services, and the completed acquisition of Advent BioServices as a wholly owned subsidiary. Other recurring developments include clinical and regulatory communications, financing arrangements, capital-structure matters, operating results, and governance changes.
Northwest Biotherapeutics (NWBO) has expanded its US technical team while eliminating selected positions to support its operational priorities.
US personnel headcount has increased overall, with operating costs remaining in the same range. Recent hires include a Quality Assurance and Regulatory Affairs Manager, a Director of Information Technologies and a Manager of Investor Relations. Priorities include scaling production capacity, including restarting US manufacturing to provide additional or backup capacity for the UK, and preparing clinical trials beyond brain cancer. One US employee position has been terminated; further cuts may follow the continuing personnel review. A similar review in the UK includes adding needed expertise and reducing other personnel.
Northwest Biotherapeutics (NWBO) has entered a collaboration with NHS Blood and Transplant to support UK production of experimental cancer vaccine DCVax-L. The work involves Advent Bioservices and initially covers Leeds and Oxford.
NHSBT's Therapeutic Apheresis Services teams collect the immune-cell starting material through leukapheresis, a procedure that separates specific white blood cells and returns the remaining blood components to the patient. Its Cellular and Molecular Therapies teams provide cell processing and handling for the next stages of personalized manufacturing.
The organizations are exploring phased expansion to additional NHSBT locations across England and broader collaboration using NHSBT's specialist laboratory and advanced-therapy capabilities. These additional activities remain exploratory.
Northwest Biotherapeutics (NWBO) announced an invited keynote presentation by Chief Technical Officer Dr. Marnix Bosch at the NHS CancerCare Oncology Conference. The presentation, titled “Harnessing Immunity: A Personalised, Multi-Target Approach to Cancer,” is scheduled for October 6, 2026, at 11:30 a.m. UK time.
Bosch will discuss personalized cancer vaccines, dendritic cell-based vaccines such as DCVax, clinical trial results and potential combination treatments. The company plans to post the slide deck on its website after the conference.
Northwest Biotherapeutics (OTCQB: NWBO) has entered into a non-binding Memorandum of Understanding with Saudi Pharmaceutical Industries and Medical Appliance Company (SPIMACO) to pursue a collaboration to bring DCVax-L for glioblastoma to Saudi Arabia under a contemplated revenue-sharing model.
According to Northwest Biotherapeutics, SPIMACO would interface with the Saudi Food and Drug Authority and be expected to act as commercial partner for marketing, sales and distribution, while the company supplies DCVax-L, provides regulatory data and scientific support, and retains all intellectual property. The MOU also contemplates negotiating license and technology transfer agreements to enable localized manufacturing in Saudi Arabia and possible future expansion to other indications and GCC countries. Northwest Biotherapeutics notes it has completed a 331-patient Phase III DCVax-L trial for glioblastoma, published results in JAMA Oncology, and has a marketing authorization application under review in the UK.
Northwest Biotherapeutics (OTCQB:NWBO) reported updated Phase III survival data for DCVax-L in glioblastoma using individual patient-level data and multiple independent analyses.
Propensity score matching showed a 3.4–6.3 month median survival advantage (HR 0.69–0.77, p=0.004–0.027); inverse probability weighting showed 3.4–4.3 months, all exceeding the original 2.8‑month cohort-level result. Sensitivity analyses (E Values, Rosenbaum's Gamma) suggested limited impact from unknown confounders. A 331‑patient Phase III trial is completed and an MAA for DCVax‑L in the UK remains under review.
Northwest Biotherapeutics (OTCQB:NWBO) announced that Chief Technical Officer Dr. Marnix Bosch will present “DCVax-L–Associated Survival Extension Assessed Through Propensity Score Matching Analyses” at the 2026 British Neuro-Oncology Society meeting on July 3 at 10:00 a.m. GMT.
The talk will address DCVax-L treatment and patient survival using propensity score matching. A slide deck will be posted on the company’s website. Northwest Biotherapeutics is developing DCVax-L for glioblastoma, supported by a completed 331-patient Phase III trial, JAMA Oncology publication, and a UK marketing authorization application under review.
Northwest Biotherapeutics (OTCQB:NWBO) appointed Dr. Annalisa Jenkins, OBE as Strategic Adviser to support development and expansion of its DCVax® dendritic cell cancer vaccine platform. Dr. Jenkins brings 25+ years of biopharma leadership and commercial experience.
The company has submitted a Marketing Authorization Application (MAA) to the UK MHRA for DCVax®-L in glioblastoma, completed a 331-patient Phase III trial with results published in JAMA Oncology, and finished a 40-patient Phase I trial of DCVax®-Direct with Phase II planned.
Northwest Biotherapeutics (OTCQB:NWBO) is establishing a dedicated leukapheresis clinic at The London Welbeck Hospital to address UK capacity shortages and support scale-up of its DCVax programs. The company began equipment purchases in Q4 2025, expects buildout completion by June, has received one machine, and is pursuing license applications.
The Welbeck clinic will offer procedures about four hours long, capacity for 4 patients per day, potential extended hours/weekends, and may provide services to third parties.
Northwest Biotherapeutics (OTCQB:NWBO) has begun on-site construction of the first Grade C manufacturing suite at its Sawston, UK facility. The company says the new Grade C suite will more than double the aggregate capacity of its existing Grade B suites and is viewed as a major step toward large-scale production of DCVax products.
The project timeline targets establishing manufacturing in the Grade C suite in Q2 2026, with construction taking about six months, followed by equipment installation and validation. Equipment costs are described as several million pounds, with individual machines noted at about £800,000 each new.
Northwest Biotherapeutics (OTCQB:NWBO) announced on October 24, 2025 that its acquisition of Advent BioServices Ltd. has closed and Advent is now a wholly owned subsidiary.
The deal transfers Advent's fixed assets, cryostorage equipment, intellectual property and intangibles to NWBio; 19 million NWBio securities previously issued to Advent (13.5M shares and 5.5M options) are reverting back to the company. Consideration includes £1.4 million plus the net accounts payable due to Advent, payable in installments over two years with possible acceleration after regulatory approval of DCVax-L. The company expects operational consolidation, GMP facility closure in London, reallocation to Sawston and U.S. capacity development, and manufacturing scale-up.